- Home
- ACAD vs ORLA Comparison
ACAD vs ORLA Comparison
Compare ACAD & ORLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACAD
- ORLA
- Stock Information
- Founded
- ACAD 1993
- ORLA 2007
- Country
- ACAD United States
- ORLA Canada
- Employees
- ACAD N/A
- ORLA N/A
- Industry
- ACAD Biotechnology: Pharmaceutical Preparations
- ORLA Precious Metals
- Sector
- ACAD Health Care
- ORLA Basic Materials
- Exchange
- ACAD Nasdaq
- ORLA Nasdaq
- Market Cap
- ACAD 4.0B
- ORLA 3.8B
- IPO Year
- ACAD 2004
- ORLA N/A
- Fundamental
- Price
- ACAD $25.99
- ORLA $11.05
- Analyst Decision
- ACAD Buy
- ORLA Buy
- Analyst Count
- ACAD 20
- ORLA 2
- Target Price
- ACAD $28.63
- ORLA $14.50
- AVG Volume (30 Days)
- ACAD 2.0M
- ORLA 1.3M
- Earning Date
- ACAD 08-06-2025
- ORLA 08-11-2025
- Dividend Yield
- ACAD N/A
- ORLA N/A
- EPS Growth
- ACAD 615.00
- ORLA N/A
- EPS
- ACAD 1.33
- ORLA 0.07
- Revenue
- ACAD $1,018,885,000.00
- ORLA $596,487,000.00
- Revenue This Year
- ACAD $14.01
- ORLA $170.92
- Revenue Next Year
- ACAD $11.72
- ORLA $23.64
- P/E Ratio
- ACAD $19.61
- ORLA $140.38
- Revenue Growth
- ACAD 14.41
- ORLA 116.83
- 52 Week Low
- ACAD $13.40
- ORLA $3.81
- 52 Week High
- ACAD $26.65
- ORLA $12.83
- Technical
- Relative Strength Index (RSI)
- ACAD 62.55
- ORLA 58.25
- Support Level
- ACAD $25.14
- ORLA $10.62
- Resistance Level
- ACAD $26.65
- ORLA $11.14
- Average True Range (ATR)
- ACAD 0.67
- ORLA 0.46
- MACD
- ACAD 0.04
- ORLA 0.15
- Stochastic Oscillator
- ACAD 70.27
- ORLA 91.18
About ACAD ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.
About ORLA Orla Mining Ltd.
Orla Mining Ltd is a mineral exploration company. It is engaged in the acquisition and exploration of mineral properties. The company holds three gold projects; the Camino Rojo gold and silver project in Zacatecas State, Musselwhite gold mine project located in Ontario and the South Railroad projects in Nevada, USA, and the Cerro Quema gold project in Panama. It conducts business activities in Mexico, Panama, the United States, and Canada.